Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Shares Outstanding (Diluted Average) (2021 - 2025)

Aligos Therapeutics' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 57.79% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, up 57.79%, while the annual FY2025 figure was $9.9 million, 57.79% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $9.9 million in Q4 2025 per ALGS's latest filing, down from $10.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $156.3 million in Q2 2024 to a low of $1.7 million in Q3 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $43.0 million, with a median of $42.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 95.92% in 2023, then skyrocketed 263.91% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $39.2 million in 2021, then rose by 9.05% to $42.7 million in 2022, then plummeted by 94.0% to $2.6 million in 2023, then surged by 144.38% to $6.3 million in 2024, then surged by 57.79% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Shares Outstanding (Diluted Average) are $9.9 million (Q4 2025), $10.4 million (Q3 2025), and $6.3 million (Q4 2024).